文献速递肿瘤 PET/CT放射性药物与辐射防护

纳武利尤单抗免疫治疗继发「眼黑」征

"Eye-Black" Sign Secondary to Nivolumab Immunotherapy.
PubMed 文献 · Clin Nucl Med · 2020-01-01

A 54-year-old woman with known chest wall melanoma (post-wide local excision) presented for imaging after a yearlong therapy with nivolumab. F-FDG PET/CT was performed 1 day after she completed the immunotherapy.…

要点

  • 融合图像示摄取位于眶下皮下颧部突出处并伴皮下钙化。
  • 3个月后复查摄取显著减低,提示为免疫治疗继发炎症。

主要发现

  • 最大强度投影图像示面部区域双侧相对对称性摄取。
  • 融合PET/CT图像示摄取对应眶下皮下颧部突出处,伴皮下颧部钙化。
  • 3个月后复查PET/CT示颧部摄取显著减低。

局限性

  • 本文为单例病例报告,结论基于一例患者的影像随访观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 54-year-old woman with known chest wall melanoma (post-wide local excision) presented for imaging after a yearlong therapy with nivolumab. F-FDG PET/CT was performed 1 day after she completed the immunotherapy. Maximum intensity projection images showed bilateral relatively symmetrical uptake in the facial region. On fused PET/CT images, the uptake was seen corresponding to subcutaneous malar prominence underneath the orbits (like eye-black stripe used in sports) with subcutaneous malar calcification. Repeat PET/CT performed after 3 months revealed significant decrease in the malar uptake. Interval resolution of the uptake likely suggested this being inflammatory and secondary to immunotherapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Priya S, Graham M. "Eye-Black" Sign Secondary to Nivolumab Immunotherapy. Clin Nucl Med. 2020. PMID: 31876808. doi:10.1097/RLU.0000000000002846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。